Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1674
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18498377 | OPTICALLY ACTIVE PYRROLIDINE COMPOUND AND METHOD FOR PRODUCING SAME | Non-Final OA | MITSUBISHI TANABE PHARMA CORPORATION |
| 17787964 | METHOD FOR PRODUCING SOLID ELECTROLYTE | Final Rejection | IDEMITSU KOSAN CO.,LTD. |
| 18562107 | SOTORASIB DOSING REGIMEN | Non-Final OA | AMGEN INC. |
| 17794003 | MECHANOCHEMICAL SNAr REACTIONS | Non-Final OA | nChain Licensing AG |
| 17836814 | ORAL PRODUCTS WITH REDUCED IRRITATION | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 17913259 | CENTRAL NERVOUS SYSTEM POTENTIATING COMPOSITION | Non-Final OA | SHIBAURA INSTITUTE OF TECHNOLOGY |
| 18248232 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Non-Final OA | The Research Foundation for The State University of New York |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | Non-Final OA | P2 SCIENCE, INC. |
| 18549852 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS | Non-Final OA | AstraZeneca AB |
| 18307905 | N-ACRYLOYLINDOLES AND METHODS OF USE | Non-Final OA | Versitech Limited |
| 17912228 | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | Final Rejection | ZYDUS LIFESCIENCES LIMITED |
| 18248535 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | Final Rejection | Bayer Aktiengesellschaft |
| 18763741 | THERAPEUTIC CONJUGATES | Non-Final OA | Totus Medicines Inc. |
| 17800049 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Final Rejection | Givaudan SA |
| 18025665 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | Non-Final OA | The Governing Council of the University of Toronto |
| 18543789 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Final Rejection | Mind Medicine, Inc. |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18451897 | METHODS OF TREATING BEHAVIOR ALTERATIONS | Non-Final OA | Oryzon Genomics, S.A. |
| 18273299 | BIOCIDAL MIXTURES | Non-Final OA | LANXESS Deutschland GmbH |
| 18126157 | ACTIVE PHARMACEUTICAL INGREDIENT, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | Non-Final OA | NANJING GRITPHARMACO.,LTD. |
| 18455378 | ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERS | Non-Final OA | Curio IP, LLC |
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18347815 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | Final Rejection | KALVISTA PHARMACEUTICALS LIMITED |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | Non-Final OA | SIGILON THERAPEUTICS, INC. |
| 18273991 | CRYSTAL FORM OF METHYLPYRAZOLE-SUBSTITUTED PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | CGENETECH (SUZHOU, CHINA) CO., LTD |
| 18265317 | SOLID PREPARATION | Non-Final OA | ASKA Pharmaceutical Co., Ltd. |
| 18202567 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | Non-Final OA | Ojai Energetics PBC |
| 18038968 | NICOTINAMIDE, NICOTINAMIDE PRECURSORS AND NICOTINAMIDE METABOLITES AND COMPOSITIONS THEREOF FOR REDUCING THE TIME TO RESOLUTION OF SYMPTOMS IN PATIENTS WITH COVID-19 AND OTHER VIRAL INFECTIONS | Non-Final OA | CONARIS RESEARCH INSTITUTE AG |
| 18037101 | IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. |
| 18195517 | SELF-EMULSIFYING ANHYDROUS INTRADERMAL DEPOT GEL | Final Rejection | MEDPHARM HOLDINGS, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy